1,721,214 research outputs found
Quality of life and CAR-T cell therapy in children, adolescents, and young adults with haematological malignancies
No full textNo abstract availabl
Asking patients with hematological malignancies: 'how do you feel?' Does it really provide independent prognostic information for survival?
No full textAutoimmune hemolytic anemia in a patient with acute myelogenous leukemia treated with low-dose interleukin-2 after autologous bone marrow transplantation.
No full textBlast crisis of chronic myelogenous leukemia in long-lasting systemic lupus erythematosus: regression of both diseases after autologous bone marrow transplantation.
No full text[Assistance procedures in the perinatal period that condition breast feeding at the time of discharge from the hospital]
No full textOptimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
No full textIntroduction: The current treatment landscape of chronic myeloid
leukemia (CML) is challenging for several reasons, and health-related
quality of life (HRQOL) data may be of critical importance to help
physicians and patients make more informed decisions.
Areas covered: A systematic literature search was performed in PubMed to
identify the most recent studies (between April 2016 and June 2020)
assessing the impact of tyrosine kinase inhibitors (TKIs) on adult CML
patients' HRQOL. Studies assessing treatment discontinuation were also
considered. For each study, we evaluated characteristics of CML patients
included, treatment information and basic HRQOL data, including
questionnaires used, and summary findings.
Expert opinion: Valuable information can be gleaned from recent CML
studies including a HRQOL assessment; however, major gaps remain in our
knowledge. These include, for example, a better understanding of the
impact of second- and third-generation TKIs on patients' HRQOL compared
to imatinib therapy. Also, the benefits of TKI treatment
discontinuation, in terms of symptom burden and HRQOL, are yet to be
fully elucidated. More research efforts are needed in this area to
generate high-quality evidence that can facilitate decision-making
CORRESPONDENCE: Response: The role of cytogenetic abnormalities in acute myeloid leukemia with NPM1 mutations and no FLT3 internal tandem duplication
No full textTyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review.
No full textThe main objective of this systematic review is to quantify and to summarize all studies that have included health-related quality of life (HRQOL) or, any other type of patient-reported outcomes (PROs), in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs). Nine papers were found and none of these were published before 2003. Overall, 3290 CML patients were enrolled in the studies reviewed. Four studies reported HRQOL data on patients treated with imatinib only. The most solid data in this area indicate that CML patients receiving TKIs have a worse HRQOL profile when compared to their peers, without cancer, in the general population and interventions to improve HRQOL outcomes are thus needed. Our review revealed the paucity of evidence-based data in this area. However, HRQOL assessment in these studies emphasize the unique information provided by the patient's perspective. Urgent efforts are needed to provide solid PROs data to complement current knowledge on clinical efficacy of TKIs
Use of interleukin-2 in the management of haematological malignancies: focus on minimal residual disease. Mandelli F, Capria S, Vignetti M, Meloni G.
No full textInterleukin (IL)-2 is a glycoprotein lymphokine which induces proliferation of all subclasses of T-lymphocytes, natural killer cells and lymphokine activated killer cells, differentiation of cytotoxic cells and secretion of other cytokines, especially interferon-gamma. A fundamental property of IL-2 activated effector cells is to selectively lyse freshly isolated tumour cells. Work carried out on animal tumour models and application in human therapeutics has suggested the potential value of an immunotherapeutic approach in haematological malignancies, especially in the setting of minimal residual disease. Extensive phase I/II trials have been conducted in all haematological diseases, but the most interesting results have been obtained in acute myeloid leukaemia and non-Hodgkin's lymphoma, where the possibility of achieving partial and complete responses in patients with advanced disease has been reported. The feasibility and immunomodulatory effects of IL-2 treatment in patients with minimal residual disease after high-dose chemotherapy have also been explored. However, the heterogeneity of cases treated and administration schedules used does not allow definitive conclusions to be drawn about the true impact of IL-2 treatment on the prognosis of these patients. The clearly encouraging results reported in the literature deserve further investigation from a biological and clinical point of view; until the role of IL-2 in haematological malignancies has been identified, it should be used only in the investigative setting of clinical trials
Flow cytometric measurement (H-1 Technicon) of microcytic and hyperchromic red cell populations in pediatric patients affected by hereditary spherocytosis (HS)
No full text- …
